Sickle cell disease and venous thromboembolism: What the anticoagulation expert needs to know

80Citations
Citations of this article
125Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Venous thromboembolism (VTE) is common in patients with sickle cell disease (SCD). The etiology of increased risk of VTE in SCD patients is multifactorial and is related to both traditional factors and SCD-specific factors. Traditional risk factors such as central venous catheters, frequent hospitalization, orthopedic surgeries for avascular necrosis, and pregnancy may lead to increased incidence of VTE in the SCD population. In addition, SCD itself appears to be a hypercoagulable state, and many SCD-specific factors such as thrombophilic defects, genotype and splenectomy may modify the risk of VTE. SCD complications such as acute chest syndrome and pulmonary hypertension may also be related to VTE. Anticoagulation experts should be aware of these factors to help inform prophylaxis and treatment decisions. © 2013 Springer Science+Business Media New York.

Cite

CITATION STYLE

APA

Naik, R. P., Streiff, M. B., & Lanzkron, S. (2013). Sickle cell disease and venous thromboembolism: What the anticoagulation expert needs to know. In Journal of Thrombosis and Thrombolysis (Vol. 35, pp. 352–358). https://doi.org/10.1007/s11239-013-0895-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free